Innovation Capital

In 2012, MorphoSys launched an initiative that provides capital to promising start-ups with technologies and/or product candidates close to its areas of expertise and interest. In addition, MorphoSys can support potential partners with technology, discovery, preclinical and clinical expertise.

Investment approach

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. MorphoSys’s core expertise in the intelligent design, generation and screening of diverse protein libraries can be applied to various drug classes. We have already gained expertise outside the antibody sector through activities based on our Slonomics technology.

Innovation Capital

Lara Smith-Weber

SENIOR VICE PRESIDENT, Head of Controlling, Corporate Finance & Corporate Development

Phone: +49 (0)89 89927 478

Email Contact

Please note: MorphoSys has a specific procedure for receiving and processing confidential or proprietary information from external sources. Please contact us to obtain the details of this procedure before sending any such information. For that reason, all unsolicited submissions of any kind will be treated as non-confidential and non-proprietary and MorphoSys may freely use any ideas, inventions or anything else contained in your submission.